Ipsen Biopharmaceuticals, Inc. drugs

7 results
  • increlex - mecasermin injection, solution

    (Mecasermin)
    Ipsen Biopharmaceuticals, Inc.
    Increlex treats growth failure in children aged 2 and older with severe primary IGF-1 deficiency or growth hormone gene deletion who have developed antibodies to growth hormone. Not a substitute for growth hormone therapy; not indicated for secondary IGF-1 deficiency caused by GH deficiency, malnutrition, or hypothyroidism.
  • iqirvo - elafibranor tablet, film coated

    (Elafibranor)
    Ipsen Biopharmaceuticals, Inc.
    IQIRVO treats primary biliary cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA), used in combination with UDCA or as monotherapy when UDCA cannot be tolerated. Approved under accelerated approval based on reduction of alkaline phosphatase.
  • onivyde - irinotecan hydrochloride injection, powder, for solution

    (Irinotecan Hydrochloride)
    Ipsen Biopharmaceuticals, Inc.
    Onivyde treats metastatic pancreatic adenocarcinoma in adults. Used with oxaliplatin, fluorouracil, and leucovorin as first-line therapy, or with fluorouracil and leucovorin after gemcitabine-based therapy fails. Not for use as a single agent.
  • sohonos - palovarotene capsule

    (Palovarotene)
    Ipsen Biopharmaceuticals, Inc.
    Sohonos reduces the volume of new heterotopic ossification in adults and pediatric patients (females 8+, males 10+) with fibrodysplasia ossificans progressiva (FOP).
  • somatuline depot - lanreotide acetate injection

    (Lanreotide Acetate)
    Ipsen Biopharmaceuticals, Inc.
    Somatuline Depot treats acromegaly in patients with inadequate response to surgery/radiotherapy, improves progression-free survival in adults with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and reduces rescue therapy frequency in adults with carcinoid syndrome.